Showing results (351-360 of 434) with videos related to

Sort By:
Pageof 44
Cost Effectiveness and Resource Allocation : C/E|November 11, 2021
Two decades (1998 to 2018) of collaborative human immunodeficiency virus clinical pharmacology capacity building in a resource constrained settingCharles C Maponga, Tsitsi G Monera-Penduka, Takudzwa J Mtisi, et al.
HIV Medicine|November 24, 2011
Pharmacokinetics of the nonnucleoside reverse transcriptase inhibitor efavirenz among HIV-infected UgandansS Nanzigu, J Eriksen, F Makumbi, et al.
Clinical Drug Investigation|May 31, 2007
Multiple-Dose Pharmacokinetics of Delavirdine Mesylate and Didanosine in HIV-Infected PatientsGene D Morse, Susan E Cohn, Mark J Shelton, et al.
African Journal of Laboratory Medicine|June 18, 2019
Development and validation of a high performance liquid chromatography method to determine nevirapine in plasma in a resource-limited settingFaithful Makita-Chingombe, Andrew J Ocque, Robin DiFrancesco, et al.
Tropical Medicine and Infectious Disease|July 28, 2023
Seroprevalence and Genotype Diversity of Hepatitis C Virus in the Caribbean-A ReviewMichelle G Brown, John F Lindo, Ivan E Vickers, et al.
The Journal of Antimicrobial Chemotherapy|April 4, 2017
Bone mineral density reductions after tenofovir disoproxil fumarate initiation and changes in phosphaturia: a secondary analysis of ACTG A5224sSamir K Gupta, Eunice Yeh, Douglas W Kitch, et al.
The Veterinary Clinics of North America. Food Animal Practice|April 9, 1998
Determining the burden of human illness from food borne diseases. CDC's emerging infectious disease program Food Borne Diseases Active Surveillance Network (FoodNet)F J Angulo, A C Voetsch, D Vugia, et al.
Antimicrobial Agents and Chemotherapy|February 7, 2007
Compartmental pharmacokinetic analysis of oral amprenavir with secondary peaksOlanrewaju Okusanya, Alan Forrest, Robin DiFrancesco, et al.
Pharmacogenetics and Genomics|January 19, 2017
Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202Anurag Verma, Yuki Bradford, Shefali S Verma, et al.
The Journal of Infectious Diseases|November 14, 2012
Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202Heather J Ribaudo, Eric S Daar, Camlin Tierney, et al.
Pageof 44